Reversal of type 2 diabetes through metabolic restoration: A narrative review

Abstract

Background: Type 2 diabetes (T2D) is traditionally managed as an irreversible disease with escalating polypharmacy. However, evidence increasingly shows that durable remission is achievable.
Aim: This review synthesises evidence for T2D reversal, exploring pathophysiological mechanisms and clinical interventions that achieve remission, while addressing barriers to this paradigm shift.
Methods: A narrative literature review was conducted across major academic databases focusing on T2D remission, beta-cell dedifferentiation, the twin cycle hypothesis, and clinical interventions like bariatric surgery, very-low-calorie diets and carbohydrate restriction.
Results: T2D is primarily a disease of beta-cell dysfunction and dedifferentiation driven by chronic metabolic stress, not permanent cell death. Initiated by peripheral insulin resistance and hyperinsulinaemia, it culminates in glucolipotoxicity from ectopic fat in the liver and pancreas (the twin cycle hypothesis). Crucially, this process is reversible. Clinical trials demonstrate significant remission rates through weight loss and lifestyle interventions. The DiRECT trial achieved 46% remission at 1 year via very-low-calorie diets. Carbohydrate restriction models (e.g. Virta Health) showed 17.6% remission at 2 years with significant medication reduction. Bariatric surgery provides further proof of principle with up to 80% remission. Despite this, clinical inertia and systemic barriers slow the adoption of reversal as a primary goal.
Conclusion: T2D is a reversible metabolic condition. Clinical management must shift from lifelong symptom management to strategic reversal of underlying pathophysiology through interventions that reduce insulin demand, clear ectopic fat and restore metabolic health.
Contribution: This review provides an evidence-based framework for implementing T2D reversal in clinical practice, advocating for a new standard of care.